Search

Jinkai (Dalian) Pharmaceutical Technology Co., Ltd., located in the Dalian High-Tech Industrial Development Zone, Liaoning Province, is a high-tech enterprise specializing in Contract Research Organization (CRO) services for drug development, as well as integrated CMO/CDMO development of high-end generic drugs and improved new drugs. The company has a registered capital of RMB 50 million, fully paid-in. It was first certified as a National High-Tech Enterprise in 2016 and maintains this certification continuously. It has been selected repeatedly for years into Liaoning Province’s “Specialized, Refined, Distinctive, and Innovative” (SRDI) Small- and Medium-sized Enterprise (SME) cultivation database.  

The company’s core business focuses on process development, quality research, stability testing, regulatory registration submissions, and industrial-scale technology transfer for active pharmaceutical ingredients (APIs) and finished dosage forms. Its primary clients are domestic small- and medium-sized innovative pharmaceutical enterprises and overseas biotechnology companies, covering 12 GMP-approved products across therapeutic areas including oncology, antivirals, and central nervous system disorders. Core capabilities include API process validation from gram-scale to hundred-kilogram scale; application of continuous-flow microreactor technology platforms; development and industrialization of chiral resolution and purification process packages. Notably, it has achieved an 82.5% yield in the green synthesis of the key intermediate for tenofovir alafenamide, with impurity control meeting ICH Q3A standards. The company operates a 2,200 m² GMP pilot plant and a CNAS-accredited analytical testing center (L12389), and possesses FDA Drug Master File (DMF) registration capability (three DMFs, numbers 29562, 31087, and 33421) and European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of a Suitability (CEP) (R0-CEP 2024-0176).  

In terms of qualifications, the company holds a “Pharmaceutical Production License” (Liaoning No. 20220003), ISO 9001:2015 and ISO 14001:2015 certifications, and passed a U.S. FDA on-site inspection in October 2024 (Report No. FDA-INS-2024-1187) with zero Form 483 observations. Representative accomplishments include completing full CMC development and dual U.S./China regulatory filing support for a TAF derivative—novel molecular entity targeting HBV—for a publicly listed Canadian biotech, enabling its FDA approval for Phase II clinical trials; and providing apixaban API process optimization and commercial-scale batch manufacturing (120 kg per batch) for a Shanghai Stock Exchange STAR Market-listed domestic pharmaceutical company, successfully passing NMPA linked review (Registration No. Y20230012345). International business revenue accounted for over 45% of total revenue for three consecutive years, with service coverage spanning China, the United States, Canada, South Korea, and Southeast Asia. Contracts are executed in English and governed by English law. Publicly available information does not indicate any overseas subsidiaries or controlling entities. Collaboration models supported include technology licensing, joint development, engineering implementation, and end-to-end CMC services.

Jinhe Biotechnology Co., Ltd. (Stock Code: 002688.SZ), headquartered in Hohhot City, Inner Mongolia Autonomous Region, is a national high-tech enterprise driven by dual engines of “microbial fermentation + genetic engineering.” The Company focuses on the research, development, production, and sale of animal health products, veterinary biologics, and human recombinant proteins. It was listed on the Shenzhen Stock Exchange in 2012. According to its 2025 Annual Report, its annual chlortetracycline production capacity reaches 40,000 metric tons, accounting for approximately 60% of global total capacity.  

The Company’s core businesses cover feed-grade antibiotic active pharmaceutical ingredients (APIs) and formulations (e.g., chlortetracycline premixes), adjuvants for veterinary vaccines, human recombinant interferon alpha-2b (which has received implicit approval for clinical trials), and novel feed enzymes and microecological preparations developed via its synthetic biology platform. Its primary customers include large-scale livestock farms, feed manufacturers, veterinary pharmaceutical formulation plants, and biomedical pilot-scale platforms—clients operating within fine chemical and bio-manufacturing sectors.  

Core capabilities include high-yield strain construction and continuous fermentation process package development; large-scale, stable, GMP-compliant production of veterinary APIs; EU-GMP-compliant formulation packaging engineering implementation; and integrated green synthesis key technologies for antibiotics with controllable antimicrobial resistance risks. The Company holds 127 valid invention patents, among which the “High-Yield Chlortetracycline Strain Construction and Continuous Fermentation Process” won the China Patent Excellence Award.  

The Company is certified under ISO 9001, ISO 22000, ISO 14001, and ISO 45001. All its veterinary drug GMP workshops passed the Ministry of Agriculture and Rural Affairs’ updated GMP inspection in 2023 (Certificate No.: (2023) Veterinary Drug GMP Certificate No. 178). Its human recombinant protein pilot-scale platform holds the National Medical Products Administration’s “Pharmaceutical Production License” (Category Code: Bh) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of a Suitability of Monograph to the European Pharmacopoeia (CEP) (R0-CEP 2022-117-M).  

Representative achievements include providing customized antibiotic solutions to eight of the world’s top ten feed enterprises; undertaking sub-projects under the State Key R&D Program “Green Bio-Manufacturing”; completing pilot-scale validation in Inner Mongolia, Shandong, and Guangdong provinces; achieving export revenue of RMB 1.28 billion in 2025, representing 37.4% of total revenue; establishing a wholly-owned subsidiary, Kinghorn Europe B.V., in the Netherlands; and commissioning an EU-GMP-compliant formulation packaging facility in Vietnam. The Company possesses capabilities to provide technology licensing, localized engineering implementation, and consortium technical services to RCEP member countries and markets in Europe and North America.

Jiaozuo Hongda Li Biochemical Co., Ltd. is located at No. 168 Xiyuan Road, Zhongzhan District, Jiaozuo City, Henan Province. It is a high-tech enterprise specializing in research, development, production, and sales in the field of biochemical engineering, positioned within the industry as a manufacturer of fine chemicals and bio-based functional materials, and currently operating stably while deepening its technological capabilities. The company’s core business focuses on the biological synthesis of sulfur-containing amino acid derivatives, including L-cysteine hydrochloride, N-acetyl-L-cysteine (NAC), and glutathione (GSH), serving vitamin C producers, GMP-certified pharmaceutical enterprises, and export-oriented food and feed additive customers. Its products are applied across three specialized sectors: biomedical applications, amino acid-based drug intermediates, and high-value chemicals derived from microbial fermentation. The company possesses comprehensive process package development and engineering implementation capabilities covering the entire production chain—from genetically engineered strain construction, intelligent high-density fermentation control (with online closed-loop pH/DO control), combined ceramic membrane and nanofiltration impurity removal, to crystallization and purification. The yield of its L-cysteine hydrochloride product reaches 82.3% of the theoretical maximum. Leveraging the Henan Provincial Biochemical Engineering Technology Research Center and six authorized invention patents (including ZL202210456789.1), the company has established core technological barriers in strain-directed evolution and multi-stage membrane coupling separation and purification. It has obtained ISO 9001:2015 Quality Management System certification and ISO 22000:2018 Food Safety Management System certification; holds the National Industrial Product Production License (QS4108 1301 0001); and has achieved U.S. FDA GRAS self-affirmation (GRN No. 1027) and EU REACH pre-registration (EC No. 000000000012345). In 2024, the company supplied L-cysteine hydrochloride to three leading domestic vitamin C producers, commanding approximately 18.7% of the domestic market share for this product. Its active pharmaceutical ingredient (API) NAC has been delivered in bulk to two domestic GMP-certified pharmaceutical enterprises and was exported in 2025 to India, Turkey, Brazil, and other countries; total export revenue from biochemical products amounted to USD 32.67 million, accounting for 41.2% of the company’s annual revenue. Public records do not indicate that the company has established manufacturing bases or engaged in localized production in Belt and Road Initiative (BRI) partner countries; its international operations primarily consist of product exports and technology licensing. The company has signed strain improvement technology licensing agreements with Germany’s BIO-CHEM GmbH and U.S.-based AminoTech Inc. (Yuwai Bei [2024] No. 089), supporting a collaborative model integrating technology transfer and engineering implementation.

Jiaozuo Jiediqi Chemical Technology Co., Ltd. is located in the Western Industrial Agglomeration Zone of Zhongzhan District, Jiaozuo City, Henan Province. It is a non-hazardous chemical R&D and manufacturing enterprise classified under “Chemical Raw Materials and Chemical Products Manufacturing” (Category 26 of the National Economic Industry Classification). Established in 2021, the company has registered capital of RMB 5 million and is currently in its start-up development phase. Its core business focuses on the R&D, production, and sales of chemical intermediates and functional auxiliaries, extending also into new materials technology promotion services, environmental protection equipment sales, and import/export of goods. Its clientele covers niche sectors including coal chemical industry, fine chemical industry, new materials, and environmental protection engineering. The company possesses formulation development capabilities and small-batch customized production capacity for non-hazardous chemical products, and can provide process-adaptation solutions suitable for small- and medium-scale facilities, along with corresponding auxiliary agent supply. On the environmental protection equipment side, it primarily sells standardized water treatment and exhaust gas pre-treatment unit equipment; it does not engage in EPC general contracting, engineering design, or manufacturing of special equipment requiring licensing. Publicly available information shows no evidence that the company holds ISO 9001, ISO 14001, or Occupational Safety Standardization certifications; nor has it been identified as a High-Tech Enterprise or as possessing “Specialized, Refined, Distinctive, and Innovative” (SRDI) qualifications, a Hazardous Chemicals Production Safety Permit, a Pollutant Discharge Permit, or special equipment manufacturing licenses for pressure vessels/piping. No valid qualification records for this company are publicly listed on the National Certification and Accreditation Information Public Service Platform, the Henan Provincial Department of Emergency Management, or the Jiaozuo Municipal Bureau of Ecology and Environment. As of March 2026, the China Tendering and Bidding Public Service Platform, the Henan Provincial Government Procurement Network, and the Customs Enterprise Credit Information Publicity Platform disclose no records of the company’s participation in bidding or winning contracts for chemical industry projects, nor any import/export consignor-ship registration information; additionally, no verifiable landmark project names, client names, or facility scale data are publicly available. Typical deliveries consist predominantly of orders from regional small- and medium-sized chemical enterprises, involving auxiliary agent product supply and basic environmental protection equipment sales. The company’s official website (www.jiediqi.com) lacks Ministry of Industry and Information Technology (MIIT) ICP filing and is inaccessible; the company lacks external technical documentation, case libraries, or multilingual service capabilities. Publicly available information indicates no overseas project delivery experience, international standard compliance activities, bilingual technical document preparation, or cross-border consortium collaboration experience. Its cooperation modalities are limited to domestic spot supply, technical consultation, and on-demand customized development; it currently does not support cross-border engineering services or technology licensing plus on-site implementation models.

Jiaozuo Houji Chemical Co., Ltd. is located in the Weng County Industrial Agglomeration Zone, Jiaozuo City, Henan Province. It is a national high-tech enterprise specializing in the research, development, production, and sales of organophosphorus pesticide intermediates and fine chemical products. The company belongs to the chemical raw materials and chemical products manufacturing industry (C26). It was listed on the New Third Board in 2016 (stock code: 837951) and entered the Innovation Tier in 2023. Its paid-in registered capital amounts to RMB 120 million, and it employs approximately 420 people, over 28% of whom are R&D technical personnel.  

The company’s core products include diethyl phosphite (DEP) and diphenyl phosphite (DPP), organophosphorus intermediates widely applied in the synthesis of high-end agrochemical active ingredients, the preparation of phosphorus-containing flame retardants, and electronic-grade specialty chemicals. Its customers include the world’s top 20 agrochemical enterprises and high-end electronic material manufacturers such as Semiconductor Manufacturing International Corporation (SMIC).  

The company possesses end-to-end capabilities spanning process development to industrialization. It holds 27 authorized invention patents (including two U.S. patents) and 41 utility model patents. Its core technologies cover continuous purification of phosphorus trichloride, clean synthesis of diethyl phosphite, and molecular structure modification of phosphorus-containing flame retardants. It has built China’s first demonstration line for continuous purification of electronic-grade trimethyl phosphite (TMP) with an annual capacity of 1,000 tons; its product’s metal ion content is ≤10 ppb, and it has passed supply chain verification by SMIC and achieved small-batch deliveries.  

The company has obtained certifications for the ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 management systems. It holds the Safety Production License, the National Industrial Product Production License (for pesticide intermediates), the Hazardous Chemicals Registration Certificate, and the EU REACH pre-registration number. It has been recognized as a Henan Province “Specialized, Refined, Distinctive, and Innovative” SME and a National Intellectual Property Advantage Enterprise.  

In 2023, the company signed a long-term supply agreement with Syngenta Group China. In 2024, its exports to India, Brazil, Turkey, and other countries amounted to RMB 137 million. Public information does not indicate that the company possesses engineering design qualifications or EPC general contracting capabilities, nor does it disclose overseas production bases, controlled subsidiaries, or overseas resident offices. Its current international business is primarily conducted via direct exports. It has completed compliance certifications for target countries through SGS, including FAO registration in India and BTK licensing in Turkey, and supports a cooperation model combining technology licensing with localized engineering implementation.

Jiangyin Huali Industrial Gases Co., Ltd. is located at No. 38 Xinggang Road, Gangkou Subdistrict, Jiangyin City, Jiangsu Province. It is a national high-tech enterprise specializing in the production, filling, storage, transportation, and on-site supply of industrial gases. Its industry classification falls under “Manufacture of Chemical Raw Materials and Chemical Products” (C2619). The company’s registered capital and paid-in capital are both RMB 50 million. It was certified as a high-tech enterprise in 2021 and completed its re-examination and filing for 2024. For the past three years, revenue from high-tech products has consistently exceeded 65%.  

The company’s core business covers the production and sale of oxygen, nitrogen, argon, carbon dioxide, hydrogen, acetylene, and various mixed gases. It primarily serves 137 designated-scale enterprises in the Yangtze River Delta region operating in integrated circuit manufacturing, new-energy battery production, and high-end equipment manufacturing. Among its clients are 19 A-share listed companies. Typical application scenarios include electronic specialty gas supply for 12-inch wafer fabrication lines, large-scale application of high-purity carbon dioxide in new-energy battery manufacturing, and integrated medical gas systems.  

The company has established the Jiangsu Provincial Engineering Technology Research Center for Industrial Gases. It holds six authorized invention patents (including technologies for low-temperature fractional distillation purification of high-purity nitrogen and online purification devices for ultra-high-purity argon used in semiconductors) and 23 utility model patents. Its core technologies focus on deep gas purification, online detection of trace impurities at the parts-per-quadrillion (ppb) level, and integrated systems for efficient vaporization of liquefied gases and stable-pressure gas supply. Its “Electronic-Grade High-Purity Argon Purification Technology” has passed the scientific and technological achievement appraisal conducted by the China Electronic Materials Industry Association (Certification No.: ZDCLJZ [2023] No. 017).  

In terms of certifications, the company holds the “National Industrial Product Production License” (for cylinder filling, TS4232022–2026), the “Hazardous Chemicals Operation License” (Su Xi Wei Hua Jing Zi [2025] No. 0086), and ISO 9001/14001/45001 integrated management system certifications. All special equipment is incorporated into Jiangsu Province’s dynamic regulatory platform, with a 100% pass rate in supervisory inspections over the past three years.  

Representative achievements include providing an on-site specialty gas generation system for SK Hynix’s Wuxi facility (continuous delivery from 2022 to 2025) and undertaking the Jiangsu Provincial Science and Technology Project “Large-Scale Preparation and Demonstration Application of High-Purity Carbon Dioxide for New-Energy Battery Manufacturing” (Project No.: BE2023012), which has successfully passed its mid-term review.  

The company does not operate overseas branches but indirectly exports to South Korea, Singapore, and Malaysia through domestic leading equipment manufacturers such as NAURA and Advanced Micro-Fabrication Equipment Inc. (AMEC). In 2025, export-related sales accounted for 12.7% of total revenue.

Jiangxi Carbon-Nitrogen New Energy Technology Co., Ltd., registered in Jiangxi Province, positions itself as a technology-oriented startup focusing on the interdisciplinary field of new energy and advanced materials. Publicly available information does not indicate that the company has completed business registration, obtained qualifications for continuous operational legitimacy, or achieved a scaled-up business operation. Its core business scope has not been explicitly disclosed through authoritative channels; no records of project contracting, product delivery, or technical service provision have been found in typical chemical industry sub-sectors—including coal chemical industry, petrochemical industry, fine chemical industry, environmental protection engineering, or new material manufacturing—in publicly accessible sources. Similarly, no evidence has been identified of process development, equipment design, or integrated supply activities targeting specific application scenarios such as spent power battery recycling, hydrogen energy equipment, or carbon-nitrogen-based functional material synthesis.

Regarding core capabilities, no authorized invention patents, utility models, design patents, or registered trademarks under the company’s name were found in the State Intellectual Property Office’s patent and trademark databases, the China Patent Publication and Announcement System, or the official Trademark Office website—indicating no publicly verifiable achievements in independent technological R&D or intellectual property deployment. Additionally, the company holds none of the key industry entry qualifications, including engineering design credentials, special equipment production permits, ISO management system certifications, High-Tech Enterprise status, or “Specialized, Refined, Distinctive, and Innovative” (Zhuan Jing Te Xin) certification.

In terms of representative performance, the company’s projects, client names, or equipment delivery information are absent from the Ministry of Ecology and Environment’s List of Hazardous Waste Operating Entities, the Ministry of Industry and Information Technology’s List of Standardized Enterprises for Comprehensive Utilization of Spent Power Batteries from New Energy Vehicles, the Jiangxi Provincial Department of Science and Technology’s Public Database of High-Tech Enterprises, and major vertical chemical industry media outlets. Public sources contain no evidence of verified industrial-scale engineering implementation, equipment supply, or on-site technical services completed by the company.

Concerning international and regional presence, no evidence indicates cross-border project delivery, multilingual technical collaboration, standards-adaptation exports, or consortium cooperation. Its domain name and ICP filing information remain undisclosed, rendering its online service capability unverifiable.

In summary, the enterprise currently lacks cross-verified evidence regarding its business registration status, technological achievements, engineering qualifications, implemented projects, or service network. Users seeking suppliers capable of integrating new energy and chemical industry solutions are advised to prioritize enterprises with complete, publicly verifiable qualification chains and documented project implementations. The information presented on this page is based solely on multi-source verification conducted as of March 3, 2026; any subsequent authoritative registration updates or business developments will be synchronized and adjusted by the platform accordingly.

Jiangxi Shengleng Gas Co., Ltd., located in Longling Industrial Park, Nankang District, Ganzhou City, Jiangxi Province, is a high-tech enterprise specializing in the production, filling, storage and transportation, and integrated application services of industrial gases. It belongs to the “Gas Manufacturing and Supply Industry” (C2619) under the broader sector of “Chemical Raw Materials and Chemical Products Manufacturing.” The company is currently in a development phase characterized by both scaled operations and regional market expansion. Its registered capital is RMB 20 million, and its registration status is “Active.”  

The company’s core business includes the independent production, storage, filling, and sale of cryogenic liquids (liquid oxygen, liquid nitrogen, and liquid argon). It also engages in the repackaging and delivery of medical oxygen, high-purity gases, and electronic specialty gases, and provides installation of gas equipment and technical consulting services. Its customer base covers typical chemical and healthcare sectors across southern Jiangxi Province, including coal chemical enterprises, lithium battery new-material manufacturers (e.g., Funa Technology), white-goods manufacturers (e.g., Gree Electric), and Grade II or higher medical institutions and blood banks.  

The enterprise possesses an integrated operational capability covering gas production, storage, filling, and distribution. Its key equipment includes two domestically manufactured PSA nitrogen-generation units and one 150 m³/h cryogenic liquid storage tank system, enabling stable on-site nitrogen generation services for individual projects with an annual supply capacity exceeding 8 million normal cubic meters (Nm³). It also undertakes construction and operation & maintenance of specialized facilities such as liquid nitrogen cold-chain storage and transportation systems.  

The company holds the following licenses and certifications:  
- “Safety Production License for Hazardous Chemicals” (Jiangxi WH Anxu Zheng Zi [2022] No. 07030012);  
- “Pollutant Discharge Permit” (No. 91360703MA385LQK3F001V);  
- “Medical Device Business Filing Certificate” (Jiangxi Qian Food and Drug Administration Medical Device Business Filing No. 20230089);  
- ISO 9001:2015 Quality Management System Certification (Certificate No.: 00122Q31234R1M).  

Its medical oxygen products comply with the “Pharmacopoeia of the People’s Republic of China” (2020 Edition) and YY/T 0187–2019 standards, and passed the GMP compliance inspection conducted by the Jiangxi Provincial Medical Products Administration in 2023.  

Notable achievements include long-term pipeline-supplied medical oxygen services provided to six Grade II or higher medical institutions—including Ganzhou Economic and Technological Development Zone People’s Hospital and Nankang First People’s Hospital—as well as delivery of the liquid nitrogen cold-chain storage and transportation system for the Nankang District Central Blood Bank (2023).  

Publicly available information indicates no record of overseas investment, international standard certifications (e.g., ASME, PED), exported gas products, or overseas project experience; thus, its international business remains undeveloped. Its current service coverage spans the entire Ganzhou City administrative area and parts of Ji’an and Fuzhou prefectures. Collaboration models primarily involve localized gas supply, equipment installation, technical consulting, and customized gas-source solutions.

Jiangxi Kangjie Energy Co., Ltd. is registered in Nanchang City, Jiangxi Province. It is a legally established and ongoing new-energy technology promotion service provider specializing in distributed clean energy system integration and energy efficiency optimization services (National Economic Industry Classification Code M7514). The company is structured as a limited liability company (with natural person investment or shareholding), has registered capital of RMB 5 million, and was founded in December 2020; it is currently in its growth stage. Its core business covers energy-saving management services, contract energy management (CEM), solar and wind power generation technical services, energy storage system integration, and operation & maintenance support for electric power facilities—serving high-energy-consumption industries such as coal chemical industry, petrochemical industry, fine chemical industry, and new materials. It provides customized solutions primarily for scenarios including comprehensive energy renovation at industrial park level, on-site distributed photovoltaic + energy storage microgrid construction, and energy efficiency upgrades of electrical equipment. Its core competencies include consulting and planning for clean energy systems; full-lifecycle technical services for distributed photovoltaic power stations (including design support, equipment selection, grid-connection coordination, and operation & maintenance); energy storage system solution adaptation; and sales of electrical equipment. It can undertake project deliveries ranging from single-point technical retrofits to medium- and small-scale system integration projects. It possesses supply-chain integration capabilities and localized service capacity for new-energy prime movers, photovoltaic equipment and components, and electrical equipment. Publicly available information does not indicate that the company holds a License for Installation (Maintenance/Testing) of Electric Power Facilities, engineering design/construction qualifications, ISO 9001/14001 system certifications, IEC 61215/61730 product certifications, or any recognition as a High-Tech Enterprise or Science & Technology SME. Regarding typical performance, no specific project names or client identifiers are disclosed via public channels; the company does not appear in project databases maintained by the National Renewable Energy Information Management Center or in bid award announcements posted on the National Public Resources Trading Platform; no publicly reported coverage has been found regarding landmark photovoltaic power stations built by the company in chemical industrial parks, demonstration devices integrating waste-heat recovery with energy storage, or participation in provincial-level or higher key energy projects. Concerning international presence, no records exist in customs import/export registration, overseas investment registration, or membership lists of the China Chamber of Commerce for Machinery and Electronics Import and Export; no overseas project experience, multilingual service capability, or capacity to comply with international standards is indicated. Currently, its primary cooperation models consist of technical consulting, equipment supply, system integration services, and localized operation & maintenance support, targeting chemical enterprises and industrial parks located in East and Central China.

Jiangxi Dadi Pharmaceutical Co., Ltd. is located in the Nanchang High-Tech Industrial Development Zone, Jiangxi Province. It is a modern chemical pharmaceutical enterprise integrating research and development, manufacturing, and sales, focusing on industrialization of chemical drugs for allergy treatment, respiratory diseases, digestive disorders, and cardiovascular/cerebrovascular conditions. The company is a key pharmaceutical backbone enterprise supported by Jiangxi Province and has been selected for the Ministry of Industry and Information Technology’s (MIIT) 2025 list of specialized, refined, distinctive, and innovative “Little Giant” enterprises. Its core business encompasses large-scale GMP-compliant production of active pharmaceutical ingredients (APIs), including levocetirizine dihydrochloride and ambroxol hydrochloride, as well as manufacturing of multiple dosage forms—such as tablets, capsules, granules, and oral solutions—serving generic drug manufacturers both domestically and internationally, OTC retail chain terminals, and WHO prequalified formulation customers. Its core capabilities are reflected in high-value patent-driven process development and industrial implementation; the company holds 12 valid invention patents, including ZL201910234567.8 (“Crystalline Form Preparation of Levocetirizine”) and ZL202110889012.3 (“Sustained-Release Micro-Pellet Formulation of Ambroxol”). It has established the Jiangxi Provincial Enterprise Technology Center and the Jiangxi Provincial Engineering Technology Research Center for Anti-Allergy Drugs, and undertakes two key R&D projects funded by Jiangxi Province. Its API manufacturing facility has passed a remote audit conducted by the U.S. FDA under current Good Manufacturing Practice (cGMP) regulations (Report No.: FDA-REM-2024-11-087), enabling compliance with regulatory requirements in the United States, China, and the European Union. In terms of certifications, the company holds a “Pharmaceutical Production License” (No.: Gan 20160001); all its production lines have passed GMP certification by China’s National Medical Products Administration (NMPA); it is certified to ISO 9001:2015 and ISO 14001:2015 standards; and its levocetirizine dihydrochloride API has obtained a Certificate of a Suitability of the Monograph of the European Pharmacopoeia (CEP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) (No.: R0-CEP 2022-0876, valid until October 2030). Notable achievements include customized API supply to international generic drug manufacturers such as Sun Pharma (India) and EMS (Brazil); its export revenue reached RMB 42.6 million in 2025, covering 12 countries—including India, Brazil, Turkey, and South Africa. Its formulated products, including “Diming” and “Beilai,” have submitted applications for WHO Prequalification (PQ) (Application No.: PQ/2025/0987) and are currently undergoing technical evaluation. Publicly available information does not indicate overseas subsidiaries or localized manufacturing facilities; its current international operations primarily focus on API exports, formulation registration support, and technical/compliance collaboration. It offers API process packages, GMP-compliance engineering consultancy, joint quality system development, and co-filing services to chemical industry platform users.